15 August 2025
The US Food and Drug Administration (FDA) has approved Vizz, manufactured by Lenz Therapeutics, for the treatment of presbyopia.
It is the first time that the FDA has approved an ophthalmic solution using aceclidine as the active ingredient for the treatment of presbyopia.
Aceclidine works by contracting the iris sphincter muscle and extending the depth of focus without causing a myopic shift.
Vizz clinical investigator, Dr Marc Bloomenstein, described the FDA approval as a “paradigm shift” in treatment options for people with presbyopia.
“I believe this will be a welcome solution for both optometrists and ophthalmologists who will now be able to offer a highly effective and sought-after presbyopia treatment,” he said.
The FDA approval follows three randomised, controlled trials exploring the safety and efficacy of the ophthalmic solution.
The trials found that Vizz demonstrated the ability to improve near vision within 30 minutes, with effects lasting up to 10 hours.
The majority of adverse reactions reported during the trials were mild, transient and self-resolving, with installation site irritation, dim vision and headache the most commonly reported side effects.
Comments (2)
You must be logged in to join the discussion. Log in
Anonymous27 August 2025
Now then...it's a "paradigm shift"!
ReportLike0
Anonymous22 August 2025
This seems to be a miotic causing a pinhole effect. Hardly rocket science.
ReportLike5